- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05831917
MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yangkun Luo
- Phone Number: 13518161979
- Email: 621199521@qq.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Sichuan Cancer Hospital and Research Institute
-
Contact:
- Yangkun Luo
- Phone Number: 13518161979
- Email: 621199521@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-70 years old;
- I-IVb stage oral cancer, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer confirmed by histopathology or cytology (AJCC 8th edition);
- Receiving radical synchronous radiotherapy and chemotherapy;
- According to the RECIST version 1.1 evaluation criteria, at least one measurable lesion is present;
- ECOG PS score 0-1;
- Hematology indicators are basically normal: white blood cell count ≥ 4 × 109/L; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Hemoglobin ≥ 90g/L; Kidney function is basically normal: serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl)>60 mL/min (using Cockcroft Fault formula): Female CrCl=(140 age) × Body weight (kg) × 0.85 / (72 × Scr mg/dl); Male CrCl=(140 age) × Body weight (kg) × 1.00 / (72 × Scr mg/dl) Liver function is basically normal: serum total bilirubin ≤ 1.5 × ULN; Cereal grass transaminase (AST) ≤ 2.5 × ULN; Glutamate transaminase (ALT) ≤ 2.5 × ULN;
- Having sufficient cognitive ability to complete the questionnaire survey;
- Able to understand and willing to sign a written informed consent form.
Exclusion Criteria:
- There is evidence of swallowing dysfunction (unrelated to HNSCC);
- Patients who have previously received radiotherapy for the head and neck region;
- Recurrent or metastatic patients;
- Involvement of posterior pharyngeal wall, posterior ring, and posterior pharyngeal lymph nodes;
- Previous tumor resection surgery or major head and neck surgery (excluding biopsy/tonsillectomy);
- Previous tracheotomy;
- Participated in other interventional clinical trials within 30 days prior to screening;
- Individuals with a history of other malignant tumors (excluding cured skin basal cell carcinoma)
- There are concurrent diseases with poor control (such as heart failure, severe lung disease, severe liver disease, mental illness, etc.);
- Individuals who are allergic to the use of drugs or their components in this protocol;
- Pregnant (confirmed by blood or urine HCG testing) or lactating women, or subjects of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment;
- Researchers believe that it is not suitable to participate in this study;
- Those who are unwilling to participate in this study or unable to sign an informed consent form;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
|
Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles. chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Swallowing Difficulty
Time Frame: 12 months
|
Swallowing Difficulty will be assessed by MDADI swallowing difficulty score
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCCHEC-02-2023-017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HNSCC
-
Groupe Oncologie Radiotherapie Tete et CouCompleted
-
Groupe Oncologie Radiotherapie Tete et CouUNICANCER; Center Eugene MarquisActive, not recruiting
-
Groupe Oncologie Radiotherapie Tete et CouUNICANCERActive, not recruiting
-
The Netherlands Cancer InstituteCompleted
-
SparX Biotech(Jiangsu) Co., Ltd.RecruitingSolid Tumor | CRC | HNSCC | RCCUnited States
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingBreast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid TumorsChina
-
National Cancer Institute (NCI)RecruitingGastroesophageal Junction (GEJ) Cancers | Advanced HNSCCUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompletedMRI | HNSCC | AI | RadiomicChina
-
CJ Bioscience, Inc.RecruitingMelanoma | NSCLC | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | HNSCCKorea, Republic of
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
Clinical Trials on Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
UNICANCERNational Cancer Institute, FranceRecruitingBreast Cancer | DCIS | Low Risk DCIS | Breast Conserving Surgery | Radiotherapy OmissionFrance
-
University Medical Center GroningenCatharina Ziekenhuis Eindhoven; Academisch Medisch Centrum - Universiteit van... and other collaboratorsActive, not recruiting
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands
-
Radboud University Medical CenterKoningin Wilhelmina Fonds; Maastro Clinic, The NetherlandsTerminatedSpinal MetastasesNetherlands
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownGastric CancerSingapore
-
Mediterranean Institute of OncologyUniversity of Palermo; University of MessinaRecruitingQuality of Life | Neurocognitive Deficit | Activities of Daily LivingItaly